[go: up one dir, main page]

CL2016001024A1 - Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. - Google Patents

Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.

Info

Publication number
CL2016001024A1
CL2016001024A1 CL2016001024A CL2016001024A CL2016001024A1 CL 2016001024 A1 CL2016001024 A1 CL 2016001024A1 CL 2016001024 A CL2016001024 A CL 2016001024A CL 2016001024 A CL2016001024 A CL 2016001024A CL 2016001024 A1 CL2016001024 A1 CL 2016001024A1
Authority
CL
Chile
Prior art keywords
schizophrenia
depression
diseases
treatment
pharmaceutical composition
Prior art date
Application number
CL2016001024A
Other languages
English (en)
Inventor
Jens-Uwe Peters
Ravi Jagasia
Roland Jakob-Roetne
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016001024A1 publication Critical patent/CL2016001024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

COMPUESTOS DERIVADOS DE PIRIDO[4,3-B]PIRAZÍN-2-CARBOXAMIDAS; PROCEDIMIENTO DE PREPARACIÓN; COMPOSICIÓN FARMACÉUTICA Y USO PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS, ESQUIZOFRENIA, DEPRESIÓN, ENTRE OTRAS ENFERMEDADES.
CL2016001024A 2013-11-12 2016-04-29 Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. CL2016001024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192406 2013-11-12

Publications (1)

Publication Number Publication Date
CL2016001024A1 true CL2016001024A1 (es) 2016-11-18

Family

ID=49552255

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001024A CL2016001024A1 (es) 2013-11-12 2016-04-29 Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.

Country Status (17)

Country Link
US (1) US9670206B2 (es)
EP (1) EP3068781B1 (es)
JP (1) JP6229056B2 (es)
KR (1) KR101861937B1 (es)
CN (1) CN105764901B (es)
AU (1) AU2014350371B2 (es)
CA (1) CA2929461A1 (es)
CL (1) CL2016001024A1 (es)
CR (1) CR20160142A (es)
EA (1) EA028940B1 (es)
IL (1) IL244619A0 (es)
MA (1) MA39027B1 (es)
MX (1) MX2016006052A (es)
PE (1) PE20160692A1 (es)
PH (1) PH12016500605A1 (es)
UA (1) UA117041C2 (es)
WO (1) WO2015071178A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108430986B (zh) 2015-10-26 2021-08-31 拜耳作物科学股份公司 作为有害生物控制剂的稠合双环杂环衍生物
KR20210040085A (ko) * 2018-07-31 2021-04-12 메르크 파텐트 게엠베하 Tlr7/8 안타고니스트 및 이의 용도
KR20210133984A (ko) 2019-02-26 2021-11-08 바이엘 악티엔게젤샤프트 해충 방제제로서의 축합된 비시클릭 헤테로시클릭 유도체
CN113710669A (zh) 2019-02-26 2021-11-26 拜耳公司 作为农药的稠合双环杂环衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773834A2 (en) * 2004-08-03 2007-04-18 Serenex, Inc. 2, 8-disubstituted naphthyridine derivatives
CN101356173B (zh) * 2005-11-11 2012-10-31 阿特纳赞塔里斯有限公司 新的吡啶并吡嗪和它们作为激酶调节剂的用途
JP2012519211A (ja) * 2009-03-02 2012-08-23 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節化合物としての８−置換キノリンおよび関連類似体
AR076381A1 (es) * 2009-04-22 2011-06-08 Janssen Pharmaceutica Nv Azetidinil diamidas como inhibidores de monoacilglicerol lipasa
BR112013000414A2 (pt) * 2010-07-07 2016-05-17 Univ Texas compostos proneurogênicos
CN105163727B (zh) * 2013-05-03 2018-08-17 豪夫迈·罗氏有限公司 刺激神经发生的异喹啉衍生物
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物

Also Published As

Publication number Publication date
IL244619A0 (en) 2016-04-21
PH12016500605A1 (en) 2016-06-13
MA39027B1 (fr) 2018-10-31
JP6229056B2 (ja) 2017-11-08
EA201690971A1 (ru) 2016-08-31
AU2014350371B2 (en) 2018-02-15
EP3068781A1 (en) 2016-09-21
CN105764901B (zh) 2018-06-22
UA117041C2 (uk) 2018-06-11
US20160251355A1 (en) 2016-09-01
CR20160142A (es) 2016-05-04
EP3068781B1 (en) 2017-12-20
KR20160061427A (ko) 2016-05-31
HK1223916A1 (zh) 2017-08-11
JP2016536320A (ja) 2016-11-24
WO2015071178A1 (en) 2015-05-21
MX2016006052A (es) 2016-07-18
CN105764901A (zh) 2016-07-13
PE20160692A1 (es) 2016-07-28
KR101861937B1 (ko) 2018-05-28
CA2929461A1 (en) 2015-05-21
EA028940B1 (ru) 2018-01-31
MA39027A1 (fr) 2018-05-31
US9670206B2 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CL2016001895A1 (es) Compuestos
CL2017001930A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
MX2015003140A (es) Formulaciones de enzalutamida.
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2013003052A1 (es) Compuestos derivados de 2h-pirazol[3,4-c]-quinolina, 2h-pirazol[3,4-c][1,5 o 1,7]-naftiridina y 2h-benzo[b][1,4]-oxazina, sus composiciones farmaceuticas utiles para el tratamiento de enfermedades y trastornos del aparato respiratorio, anafilaxia sistemica o respuestas de hipersensibilidad entre otras.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
MX392130B (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2018015734A (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1.
PH12014501991B1 (en) Phenicol antibacterials